Cite
Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer.
MLA
Cho, Heyrim, et al. “Study of Dose-Dependent Combination Immunotherapy Using Engineered T Cells and IL-2 in Cervical Cancer.” Journal of Theoretical Biology, vol. 505, Nov. 2020, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.jtbi.2020.110403.
APA
Cho, H., Wang, Z., & Levy, D. (2020). Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer. Journal of Theoretical Biology, 505, N.PAG. https://doi.org/10.1016/j.jtbi.2020.110403
Chicago
Cho, Heyrim, Zuping Wang, and Doron Levy. 2020. “Study of Dose-Dependent Combination Immunotherapy Using Engineered T Cells and IL-2 in Cervical Cancer.” Journal of Theoretical Biology 505 (November): N.PAG. doi:10.1016/j.jtbi.2020.110403.